Pfizer secures FDA approval for expanded use of Xalkori cancer drug
The US Food and Drug Administration has approved Pfizer's Xalkori (crizotinib) to treat a rare form of advanced non-small-cell lung cancer (NSCLC).
The drug's use has been expanded to treat patients with advanced, or metastatic, NSCLC whose tumors have an ROS-1 gene alteration, which is believed to lead to abnormal cells.
Xalkori is the first and only FDA-approved treatment for patients with the ROS-1 gene alteration.
The drug was initially approved in 2011 to treat NSCLC patients who test positive for alterations in a gene known as ALK.
Click on this link for more information.
